DNA Script — Enzymatic DNA Synthesis Pioneer

DNA Script is building the enzymatic DNA synthesis industry from Paris. The company’s SYNTAX System — a benchtop instrument that synthesizes custom DNA strands using engineered enzymes rather than toxic phosphoramidite chemistry — represents one of the most consequential biotechnology platform shifts of the 2020s. For France 2030, DNA Script is a proof of concept that French deep science can produce globally competitive frontier technology companies.

The Technology: Why Enzymatic DNA Synthesis Matters

Traditional DNA synthesis — the chemical process used to manufacture oligonucleotides for research, diagnostics, and therapeutics — relies on phosphoramidite chemistry developed in the 1980s. It requires toxic solvents (acetonitrile), harsh deprotection chemicals, low-temperature storage, and a manufacturing process that takes 24-72 hours and produces significant chemical waste. The process has barely changed in 40 years despite being a foundational tool of modern biology.

DNA Script’s enzymatic synthesis uses engineered terminal deoxynucleotidyl transferase (TdT) enzymes — proteins that naturally add nucleotides to DNA strands — modified to add specific nucleotides one at a time in a controlled, programmable fashion. The result: DNA synthesis at room temperature, in aqueous buffer, without toxic chemicals, with substantially reduced synthesis time (down to 2-4 hours for standard oligonucleotides) and higher yield for long sequences (greater than 100 nucleotides).

The commercial implications are profound:

Drug discovery acceleration: Pharmaceutical companies synthesizing 5,000-50,000 unique DNA sequences per week for high-throughput screening can dramatically reduce turnaround time
mRNA template production: mRNA drugs and vaccines require a DNA template; enzymatic synthesis produces higher-quality, longer templates than chemical synthesis
Synthetic biology: CRISPR guide RNAs, gene circuit components, and DNA data storage all benefit from higher-quality, faster synthesis
Point-of-care diagnostics: Enzymatic synthesis could ultimately enable bedside synthesis of diagnostic reagents — a decade-horizon application but scientifically plausible

Founding, Funding, and the Genopole Connection

DNA Script was founded in 2014 by Thomas Ybert and Sylvain Gariel, two researchers who met at the École Polytechnique and ESPCI Paris. The company established itself at Genopole in Évry-Courcouronnes — France’s dedicated biotechnology campus 35 kilometers south of Paris, hosting over 80 biotech companies and 20 public research laboratories. Genopole provides subsidized lab space, shared equipment access, and a concentrated peer network that has proven essential for DNA Script’s development.

The funding history reflects both the company’s exceptional technical credibility and France’s growing capacity to support deep-science companies:

2018: Series A — €18 million — Led by Sofinnova Partners (Paris), with participation from Bpifrance and BNP Paribas Développement
2020: Series B — €38 million — Led by M Ventures (Merck KGaA venture arm) and Codon Capital, with Bpifrance returning
2022: Series C — million — Led by Illumina Ventures, with Codon Capital, M Ventures, and a first commitment from Catalio Capital Management. Bpifrance co-invested €20 million specifically under the France 2030 i-Bio program
2023: Series C extension — million — Additional close bringing total Series C to million, one of the largest rounds ever raised by a French synthetic biology company

Total capital raised through 2024: approximately million. DNA Script’s investor base spans French institutions (Bpifrance, Sofinnova), strategic corporate investors (Illumina, Merck), and US life sciences specialists (Codon, Catalio) — a genuinely transatlantic syndicate that reflects the technology’s global market opportunity.

The SYNTAX System: Commercial Launch and Adoption

DNA Script launched the SYNTAX System commercially in 2022. The instrument occupies a laboratory benchtop (similar footprint to a PCR thermocycler), requires no dedicated ventilation or waste treatment infrastructure, and connects to cloud-based synthesis software.

By 2025, SYNTAX systems were operational at:

Major pharmaceutical companies: Pfizer, Roche, Eli Lilly, AstraZeneca, Novartis have each deployed multiple units in R&D laboratories
Contract research organizations: IQVIA and Covance integrated SYNTAX systems into their oligonucleotide synthesis services
Academic research centers: The Broad Institute, Institut Pasteur, and Cambridge’s Wellcome Sanger Institute are among academic early adopters
Diagnostic manufacturers: BioMérieux (France), Meridian Bioscience (US) have deployed units for diagnostic probe synthesis

Pricing model: instrument purchase plus reagent consumables — estimated €180,000-220,000 per instrument plus approximately €8-15 per synthesis cycle, depending on oligonucleotide length. Revenue is primarily consumables-driven (the classic razor-and-blades model).

Bpifrance Partnership and France 2030 Role

DNA Script’s relationship with Bpifrance extends beyond the Series C co-investment. The company received:

€5 million in i-Bio grants (2022): Non-dilutive grant from Bpifrance’s innovation funding arm, specifically for development of next-generation enzymatic chemistries for long-read DNA synthesis (greater than 200 nucleotides)
€8 million in R&D tax credits: Under France’s Crédit d’Impôt Recherche program, DNA Script recovers approximately €6-8 million annually in R&D tax reimbursements, effectively reducing French R&D costs by 30%
Genopole infrastructure access: Continued subsidized campus access worth approximately €500,000 annually in below-market rental and shared equipment

Under France 2030, DNA Script also participates in the synthetic biology workstream of the French BioEconomy Strategy — a government roadmap targeting €4 billion in French synthetic biology revenues by 2030, up from approximately €600 million in 2022.

Applications in Drug Discovery: The Pharma Angle

For investors analyzing DNA Script’s commercial opportunity, the highest-value near-term application is pharmaceutical oligonucleotide drug development. The FDA approved 12 oligonucleotide-based drugs through 2024, with 200+ in clinical development. Each requires rapid synthesis of thousands of sequence variants during optimization — a workflow where enzymatic synthesis’s speed and quality advantages are commercially decisive.

Sanofi, which has a major investment in mRNA therapeutics and RNA interference drugs through its Translate Bio acquisition, is a natural potential strategic partner or acquirer. The Genopole proximity to Sanofi’s Évry research presence makes that relationship particularly plausible.

Strategic Significance for France’s Biotech Ecosystem

DNA Script matters to France 2030 beyond its own commercial trajectory. It demonstrates that French academic research — in this case, protein engineering at ESPCI Paris — can be converted into globally competitive biotechnology platforms that raise capital in US markets. That proof of concept is essential for France’s ambition to become Europe’s leading biotech hub.

The company’s presence at Genopole strengthens that ecosystem’s claim to be a genuine cluster for synthetic biology — alongside six other France 2030-funded synthetic biology companies including Carbios (plastic biodegradation), Eligo Bioscience (precision microbiome), and TreeFrog Therapeutics (3D cell culture).